ESR1 and breast carcinoma: It has been demonstrated that CDK7 overexpression occurred in the estrogen receptor-positive, palbociclib-resistant breast cancer cells (26), suggesting that CDK7 is involved in cellular resistance to CDK4/6 inhibitors.